Estimating Standard-Dose and High-Dose Fluzone Vaccine Efficacies for Influenza A Based on Hemagglutination Inhibition Titers.

ABSTRACT:

Background

The high-dose (HD) Fluzone influenza vaccine is recommended for individuals aged ≥65 years due to its improved antibody responses and vaccine efficacy (VE) over the standard-dose (SD) formulation. Since influenza vaccines are frequently reformulated, monitoring VE changes is crucial. Traditional efficacy trials are costly and time-consuming, but immunogenicity studies using hemagglutination inhibition (HAI) titers-a reliable correlate of protection-can be used to estimate VE more efficiently.

Methods

We analyzed data from a human vaccine cohort who received either the SD or HD Fluzone split-inactivated influenza vaccine during influenza seasons 2013-2014 to 2021-2022. We used a previously developed statistical model to map pre- and postvaccination HAI titers to pr

SUBMITTER: Hammerton SM 

PROVIDER: S-EPMC12128072 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature